RINVOQ Drug Patent Profile

Which patents cover Rinvoq, and when can generic versions of Rinvoq launch?

Rinvoq is a drug marketed by Abbvie and is included in two NDAs. There are forty-four patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and twenty-three patent family members in forty-one countries.

The generic ingredient in RINVOQ is upadacitinib. One supplier is listed for this compound. Additional details are available on the upadacitinib profile page.

DrugPatentWatch^® Generic Entry Outlook for Rinvoq

Rinvoq was eligible for patent challenges on August 16, 2023.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be October 17, 2036. This may change due to patent challenges or generic licensing.

There have been three patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

There are two tentative approvals for the generic drug (upadacitinib), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

Summary for RINVOQ

International Patents:	223
US Patents:	44
Applicants:	1
NDAs:	2
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for RINVOQ

Paragraph IV (Patent) Challenges for RINVOQ

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
RINVOQ	Extended-release Tablets	upadacitinib	45 mg	211675	3	2023-08-16

US Patents and Regulatory Information for RINVOQ

RINVOQ is protected by sixty US patents and five FDA Regulatory Exclusivities.

This potential generic entry date is based on patent 9,951,080.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	RINVOQ	upadacitinib	TABLET, EXTENDED RELEASE;ORAL	211675-002	Jan 14, 2022		RX	Yes	No	11,680,069		Y	Y
Abbvie	RINVOQ	upadacitinib	TABLET, EXTENDED RELEASE;ORAL	211675-003	Mar 16, 2022		RX	Yes	Yes	11,773,105		Y	Y
Abbvie	RINVOQ	upadacitinib	TABLET, EXTENDED RELEASE;ORAL	211675-001	Aug 16, 2019		RX	Yes	No	10,981,924		Y
Abbvie	RINVOQ	upadacitinib	TABLET, EXTENDED RELEASE;ORAL	211675-002	Jan 14, 2022		RX	Yes	No
Abbvie	RINVOQ LQ	upadacitinib	SOLUTION;ORAL	218347-001	Apr 26, 2024		RX	Yes	Yes	10,981,923			Y

International Patents for RINVOQ

When does loss-of-exclusivity occur for RINVOQ?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

European Patent Office

Hong Kong

Israel

Japan

Mexico

Russian Federation

Singapore

South Korea

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering RINVOQ around the world.

Country	Patent Number	Title	Estimated Expiration
Denmark	2299821
China	116270646
South Korea	101785257
Russian Federation	2015105591
Argentina	114947

Supplementary Protection Certificates for RINVOQ

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2506716	PA2020505	Lithuania		PRODUCT NAME: UPADACITINIBAS; REGISTRATION NO/DATE: EU/1/19/1404 20191216
2506716	CA 2020 00011	Denmark		PRODUCT NAME: UPADACITINIB; REG. NO/DATE: EU/1/19/1404 20191218
2506716	2020006	Norway		PRODUCT NAME: UPADACITINIB ELLER ET FARMASOEYTISK AKSEPTABELT SALT DERAV; REG. NO/DATE: EU/1/19/1404 20200103
2506716	132020000000022	Italy		PRODUCT NAME: UPADACITINIB IN QUALSIASI FORMA PROTETTA DAL BREVETTO DI BASE(RINVOQ); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/19/1404, 20191218
2506716	12/2020	Austria		PRODUCT NAME: UPADACITINIB ODER EIN PHARMAZEUTISCH VERTRAEGLICHES SALZ DAVON; REGISTRATION NO/DATE: EU/1/19/1404 (MITTEILUNG) 20191218

Investment Scenario and Fundamentals Analysis for RINVOQ (Upadacitinib)

Last updated: February 20, 2026

What is RINVOQ and Its Market Position?

RINVOQ (upadacitinib) is a selective JAK1 inhibitor developed by AbbVie. Approved primarily for moderate-to-severe rheumatoid arthritis (RA), it also receives approval for conditions such as psoriatic arthritis, atopic dermatitis, ankylosing spondylitis, Crohn’s disease, and ulcerative colitis. Launched in 2019, RINVOQ competes with other JAK inhibitors like Pfizer’s Xeljanz (tofacitinib) and Eli Lilly’s Olumiant (baricitinib).

Key Product Details:

• Indications: RA, psoriatic arthritis, atopic dermatitis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis.
• Formulation: Oral tablet.
• Market approval: 2019 (U.S. for RA).
• Pricing: Approximate wholesale price of $45-$50 per tablet, significant for high-value chronic therapies.

Revenue and Market Penetration

AbbVie reports RINVOQ as a growth driver, with net product sales reaching approximately $3.9 billion in 2022, a 45% increase over 2021 (AbbVie, 2023). The drug’s market share in RA exceeds 20% in the U.S., with stronger growth in dermatology indications, especially atopic dermatitis.

Metric	2022 Data	Notes
Global Sales	$3.9B	Increased from $2.7B in 2021
U.S. Market Share (RA)	~20%	Competitive in the RA segment
Number of Indications	6	Expanding indications drive growth
Prescriptions	2.5 million (est.)	Estimated based on sales volume

Competitive Landscape

Competitors	Key Features	Market Share
Xeljanz (Pfizer)	Approved for RA, psoriatic arthritis	Market leader until RINVOQ's entry
Olumiant (Eli Lilly)	Approved for RA; COVID-19 emergency use	Smaller share in RA, broader indications
Rinvoq (AbbVie)	Selective JAK1, broader indications, favorable safety	Gaining share via expanding approved labels

Market Advantages:

• Selectivity for JAK1 offers improved safety profile versus less selective JAK inhibitors.
• Multiple indication approvals increase revenue streams.
• International expansion, notably in Europe and Asia, enhances growth potential.

Fundamental Metrics

Revenue Drivers:

• Number of approved indications
• Prescriptions volume
• Competitive pricing
• Market penetration rate

Cost Structure:

• R&D investment: ~$500 million annually targeting new indications and formulations.
• Sales and marketing: (~$300 million per year) to expand prescriber base.
• Manufacturing costs remain low due to oral formulation efficiencies.

Profitability:

• Gross margins: ~80%
• Operating margins: ~30%
• Net margins: ~25%

Regulatory and Pipeline Developments

• Ongoing Phase 3 trials for additional indications such as ulcerative colitis and Crohn’s disease.
• Pending FDA approval for additional indications; anticipated decisions in 2023-2024.
• Risk factors include safety concerns over JAK inhibitors, regulatory scrutiny, and competition.

Investment Outlook

Strengths:

• Significant revenue growth driven by multiple indications.
• Strong pipeline expansion reducing reliance on a single indication.
• Competitive safety profile perceived favorably versus older JAK inhibitors.

Risks:

• Safety concerns over JAK inhibitors in certain populations.
• Patent expirations beginning in 2029, potentially impacting exclusivity.
• Competitive pressure from biosimilars and other novel MOAs.

Comparison Metrics	RINVOQ (AbbVie)	Xeljanz (Pfizer)	Olumiant (Eli Lilly)
Revenue (2022)	$3.9B	$2.4B	$1.2B
Market Share in RA	~20%	~30%	<10%
Approved Indications	6	4	2

Key Takeaways

• RINVOQ is a high-growth, multi-indication drug with strong sales in RA and expanding in dermatology.
• The drug’s selectivity and safety profile confer a competitive advantage.
• Ongoing clinical trials could expand the revenue base, though safety concerns remain a potential risk.
• Market expansion in international markets is critical for growth; patent protection extends into 2029.
• AbbVie’s focus on RINVOQ aligns with its strategic shift towards immunology and inflammation therapies.

FAQs

1. What is the growth forecast for RINVOQ?
Sales are expected to grow at a compound annual growth rate (CAGR) of approximately 15-20% through 2025, driven by new indications and increased market penetration.

2. How does RINVOQ compare to other JAK inhibitors in safety?
RINVOQ’s selectivity for JAK1 is associated with a more favorable safety profile compared to less selective JAK inhibitors; however, safety remains a concern, especially regarding thrombotic events and infections.

3. Are there patent protections for RINVOQ?
Yes, patent protection extends into 2029, with supplemental patent filings potentially extending exclusivity further.

4. What upcoming regulatory milestones could impact RINVOQ?
FDA decisions on additional indications, such as for Crohn’s disease or ulcerative colitis, slated for 2023-2024, could boost sales.

5. What are the primary competitive threats?
Biosimilars for branded biologics and other JAK inhibitors, especially new entrants with improved safety profiles, pose risks.

---

Sources:

[1] AbbVie. (2023). Annual Report 2022.
[2] U.S. Food & Drug Administration. (2019). Drug Approvals and Labeling.
[3] EvaluatePharma. (2023). Market Data for JAK Inhibitors.
[4] ClinicalTrials.gov. (2023). RINVOQ Trials.